Author(s): Fonteneau JF, Guillerme JB, Tangy F, Grgoire M
Abstract Share this page
Abstract Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.
This article was published in Oncoimmunology
and referenced in Immunotherapy: Open Access